Minimal residual disease quantification in ovarian tissue collected from patients in complete remission of acute leukemia

This is the authors' abstract. We don't add key points for this paper.

Measurable residual disease evaluated by flow cytometry using leukemia associated immune phenotypes following allogeneic stem cell transplantation is associated with high relapse rates in patients with acute myeloid leukemia.Leuk Lymphoma.2020;61(3):745-748.20.US Food and Drug Administration.Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment.Available at: https://www. fda.gov/regulatory-information/search-fda-guidance-documents/ hematologic-malignancies-regulatory-considerations-use-minimal- residual-disease-development-drug-and.Accessed 23 April 2020.21.US National Library of Medicine.Evaluation of measurable residual disease in patients with acute myeloid leukemia as surrogate endpoint for survival.https://clinicaltrials.gov/show/NCT03549351.